johnnyfiber...Let me add something to this mix. Frog has spent years fighting windmills, attempting to create the impression that DNAPrint's science is somehow second rate. Yet in the face of his twisted arguments stands the ever growing number of highly respected scientists working collaboratively with DNAPrint.
The recent collaboration with Emory is an interesting example in that Dr. Mark Bouzyk only recently assumed his position at Emory. For the prior 8 years, he worked for Glaxosmithline in a position which would make him eminently qualified to pass judgement on the merits of DNAPrint's approach:
Mark Bouzyk, PhD
Director, Center for Medical Genomics, Emory University
Dr Bouzyk is the new director of the Center for Medical Genomics (CMG). The CMG is a core facility that provides state of the art laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk has come to Emory with more than eight years track record in a global pharmaceutical company, GlaxoSmithKline, where one of his roles was to serve as Director of Genetic Laboratory Sciences leading the company’s high throughput genotyping efforts in Europe.
I believe it notable that a man of his obvious credentials would provide this quote in DNAPrint's PR announcing the collaboration:
"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics,"said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.
Who to believe...Dr. Bouzyk...or Kermy...not a tough choice for me.
As always, do your own Due Diligence and make your own investment decisions.
Later,
W2P
